Medscape Conference Coverage, based on selected sessions at the:

Anxiety Disorders Association of America (ADAA) 2009 Annual Conference

March 12 - 15, 2009; Santa Ana Pueblo, New Mexico

This activity is not sanctioned by, nor a part of, the Anxiety Disorders Association of America. Conference news does not receive grant support and is produced independently.

Conference News

Agent Approved for Alzheimer's Disease May Help Severe OCD

Memantine, a drug currently approved for the treatment of moderate to severe Alzheimer's disease that is under investigation for adjunctive treatment of schizophrenia and other illnesses may also play a role in the treatment of patients with severe refractory obsessive-compulsive disorder.
Medscape Medical News, March 18, 2009
Combination Therapy Effective in Treating Late-Life Anxiety

For older patients with generalized anxiety disorder, combining a short course of cognitive-behavioral therapy with a selective serotonin-reuptake inhibitor may provide optimal long-term treatment.
Medscape Medical News, March 18, 2009
Exposure Therapy for PTSD May Benefit Older Veterans

Results from a small study suggest prolonged exposure therapy may benefit older veterans suffering from posttraumatic stress disorder.
Medscape Medical News, March 18, 2009
Breathing Technique Reduces Anxiety Related to BII Phobia

For individuals with blood-injection-injury phobia, a novel biobehavioral approach aimed at regulating breathing may lessen anxiety, new research suggests.
Medscape Medical News, March 17, 2009
Intensive Residential Treatment for OCD Helps Patients After Discharge

Individuals with severe, refractory obsessive-compulsive disorder treated in an intensive residential treatment program maintain improvements in symptoms 6 months after discharge.
Medscape Medical News, March 16, 2009

Disclaimer

The materials presented here do not reflect the views of Medscape, LLC, or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape, LLC, and do not represent a publication of the Anxiety Disorders Association of America. These materials and the related activity are not sanctioned by the Anxiety Disorders Association of America or any commercial supporters of the conference and do not constitute an official part of that conference.